Drug firm Granules India today said re-inspection of its manufacturing facility at Gagillapur in Telangana has been successfully completed by Portugal's health authority INFARMED.
Last month, Granules said it had received 11 observations from INFARMED for its Gagillapur facility. INFARMED had conducted a renewal inspection of the facility.
"After submission of the responses to the audit observation, re-inspection of the said facility was conducted by INFARMED from January 31 to February 2. We are pleased to inform that re-inspection was completed successfully," Granules India said in a regulatory filing.
Also Read
The plant manufactures pharmaceutical formulation intermediates (PFIs) and finished dosages.
Shares of Granules India were trading 7.10 per cent higher at Rs 124.50 apiece on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
